Navigation Links
Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Date:10/21/2009

CARY, N.C., Oct. 21 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it will host a conference call at 8:30 AM ET on Wednesday, November 4, 2009, to discuss its financial results for the quarter ended September 30, 2009. Management will also provide an update on the Company's strategy, operations and product development pipeline. Cornerstone intends to issue its financial results press release prior to the conference call.

To participate in the live conference call, please dial 866-831-6270 (U.S. callers) or 617-213-8858 (international callers), and provide passcode 70654905. A live webcast of the call will also be available through the Investor Relations section of the Company's website. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 10:30 AM ET on November 4, 2009, by dialing 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), and providing passcode 27145476.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Co
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)
2. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
3. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
4. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
5. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
6. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
7. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
8. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
9. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
10. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 19, 2014 The empty ... the rising ageing population and technological innovations in ... nutraceutical industries are catalysing the growth of the ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , ... well as new entrants/smaller firms to gauge the ...
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... Inc. (Nasdaq: EMIS ) has agreed to ... LLY ) to settle the pending litigation ... submit a Stipulation of Dismissal with,Prejudice of their ... the,Southern District of Indiana. Additional terms and conditions ...
... Morria Biopharmaceuticals Plc, a,private biopharmaceutical company ... announced it has appointed Dr.,Johnson Lau and ... directors. Dr. Johnson Lau (MBBS, MD, ... the,medical, pharmaceutical and corporate fields, having a ...
... f-star, an antibody,engineering company developing novel antibodies ... Antibody Technology, today announced the,appointment of Dr. ... Mudde has,over 20 years of experience in ... research and development. He comes to f-star,from ...
Cached Biology Technology:Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation 2Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors 2Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer 2
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... food becomes scarce, animal populations exploit a wider range ... at different sites in California,s coastal waters were not ... population is higher where food is limited. But this ... sea otters, which instead showed dietary specialization in response ...
... some of the genetic secrets that enable pine ... disease, uncovering critical new information about forests natural ... this genetic analysis will allow forest stewardship programs ... that could in time repel insects such as ...
... --- Mother Nature regulates critical cellular activities in plants ... specific biochemical reactions. Looking to learn from nature, a ... million grant from the Air Force Office of Scientific ... for military and civilian applications. The grant ...
Cached Biology News:Sea otter study reveals striking variability in diets and feeding strategies 2Sea otter study reveals striking variability in diets and feeding strategies 3UBC discovery unlocks tree genetics, gives new hope for pine beetle defense 2Team of chemists receives $5 million grant to develop enzyme mimics 2
... StabilZyme HRP Conjugate Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... 6.7. This product contains a ... 20 ppm Proclin 300 (Rohm and Haas ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... V-106 voice-coil scanning and positioning system ... samples have to be positioned or ... resolution. It provides superior responsiveness compared ... The mechanics (X or XY stage) ...
Biology Products: